After weight loss, regular exercise rather than GLP-1 drug reduces leading cause of heart attacks and strokes

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity—a leading underlying cause of cardiovascular disease.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup